South China Morning Post
GSK licenses Chinese firm’s cancer drug in US$750 million deal
British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in biotechnology. GSK announced plans on…
View original source — South China Morning Post ↗
Related stories
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times
South China Morning Post
HealthSep 9, 2026 · 1 min
Hong Kong targets biomedicine powerhouse status in debut five-year plan
South China Morning Post
Bloomberg
HealthJun 9, 2026 · 1 min
GSK Agrees to Buy Nuvalent for $10.6 Billion
Bloomberg
The Guardian
HealthJun 9, 2026 · 1 min
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
The Guardian